Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
In this week’s episode of the Bowtied Biotech Podcast, we tackle a whirlwind of major biotech and pharma news shaping the industry. From Donald Trump’s nomination of Robert F. Kennedy Jr. to lead HHS—a move that sent shockwaves through the healthcare and vaccine sectors. We will also review high-stakes licensing deals like Merck’s $3 billion bet on PD-1/VEGF bispecifics and BioNTech’s acquisition of Biotheus for a dual-targeting oncology therapy. Then we will explore the latest in obesity biotech funding, new developments in GLP-1 treatments, and the challenges facing established players like Biogen as they navigate competitive pressures and shifting market dynamics. Join us as we connect the dots between politics, innovation, and the evolving landscape of healthcare.
📣🎙️ TODAY’S POCAST:
[ 0:07 ] Intro
[ 0:33 ] Pharma Industry Deep Dive
[ 1:03 ] FDA Shakeups: Trump & RFK Jr.
[ 1:28 ] Impacts of RFK Jr.'s Leadership on Pharma
[ 2:49 ] Catalent Acquisition: Novo Holdings’ Big Move
[ 3:43 ] Merck’s $3B Bet on Bispecific Antibodies
[ 4:39 ] Neurodegenerative Advances: GSK & Vesalius
[ 5:50 ] Biogen’s Leqembi Struggles
[ 7:18 ] Obesity Treatments: GLP-1 Innovations & Metsera
[ 8:29 ] Kennedy’s Broader Vision for Pharma
[ 9:57 ] Innovation vs. Regulation: The Push and Pull
[ 11:59 ] Personalized Medicine: A Shifting Paradigm
[ 14:00 ] Careers in Biotech: Breaking In
[ 17:58 ] Key Takeaways: Innovation, Regulation & Impact
[ 18:41 ] Outro
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post